WSI Reports 52% YoY Increase in 2Q Operating Profit... "Strong Sales of Key Products"

WSI, a specialized company in pharmaceutical and medical device distribution, recorded strong performance in the second quarter of this year.

On the 16th, WSI announced that it achieved consolidated sales of 15.2 billion KRW and operating profit of 2.1 billion KRW in the second quarter. These figures represent increases of 17% and 52%, respectively, compared to the same period last year. Net profit for the same period was 1.9 billion KRW.

The continuous sales growth of the flagship product, topical hemostatic agents, led to significant external growth. Increased sales of existing products such as adhesion barriers, spinal endoscopes, and bone hemostatic agents also contributed to improved performance. Additionally, sales of products from ZimVie, a U.S. company, in the newly launched spinal implant business this year drove the increase in sales.

However, net profit decreased due to increased expenses related to the relocation to a new headquarters, reduced valuation gains on derivatives (convertible bonds), and decreased financial income.

A company representative stated, "We smoothly achieved the first half sales target for topical hemostatic agents set at the beginning of this year, which significantly improved sales. Based on the specialized hospital network and sales capabilities accumulated over a long period in the spinal field, we expect the newly launched spinal implant business to gradually expand."

He added, "We will actively pursue diversification of spinal-related pharmaceutical and medical device product lines and discover high-growth businesses to strengthen our mid- to long-term competitiveness."

This content was produced with the assistance of AI translation services.